Trial Profile

Phase 3 clinical study of SYN-2510/IMM2510 in combination with chemotherapy in first-line non-squamous and squamous NSCLC and/or first-line TNBC

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 16 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palverafusp alfa (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
Focus Therapeutic Use

06 Jan 2026 According to an Instil Bio media release, company has decided to discontinue clinical development of AXN-2510, and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. have entered into an agreement to terminate their license and collaboration arrangement for AXN-2510 and AXN-27M.
22 May 2025 According to the Instil Bio Media Release, company anticipated to start in mid-2026 in China, subject to regulatory discussions
18 Sep 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com